AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2011
Apr 22, 2011
33651_dirs_2011-04-21_4ea00d98-573f-4bf6-ae4f-f93d943d8783.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-03-31
Reporting Person: Ahn Mark J (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-03-31 | Stock Option | $1.38 | A | 100000 | Acquired | 2021-03-30 | Common Stock (100000) | Direct |
| 2011-03-31 | Stock Option | $1.38 | A | 525000 | Acquired | 2021-03-30 | Common Stock (525000) | Direct |
Footnotes
F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.
F2: Per share.
F3: 300,000 of the options vest in 8 quarterly installments of 37,500 beginning on June 30, 2011. 50,000 of the options vest upon the Company's common stock trading at a minimum closing price of $3.00 per share for 30 consecutive days. 75,000 of the options vest upon the Company's common stock trading at a minimum closing price of $4.00 per share for 30 consecutive days. 100,000 of the options vest upon the Company's common stock trading at a minimum closing price of $5.00 per share for 30 consecutive days.